Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

50 results about "Lantibiotics" patented technology

Lantibiotics are a class of polycyclic peptide antibiotics that contain the characteristic thioether amino acids lanthionine or methyllanthionine, as well as the unsaturated amino acids dehydroalanine, and 2-aminoisobutyric acid.

Export and modification of (poly)peptides in the lantibiotic way

The invention includes a method for harvesting a polypeptide produced by a host cell, wherein the polypeptide has not undergone intracellular posttranslational modification, such as dehydration of a serine or a threonine, and / or thioether bridge formation. The invention also includes a method for producing thioether-containing peptides and dehydroalanine / dehydrobutyrine-containing.peptides, wherein thioether rings may be formed extracellularly.
Owner:APPLIED NANOSYST

Composition having bacteristatic and bactericidal activity against bacterial spores and vegetative cells and process for treating foods therewith

Antibacterial compositions effective against both gram positive and gram negative vegetative bacteria plus harmful gram positive sporeforming bacteria include propionibacterial metabolites in combination with two or more of the following: a lantibiotic; a lytic enzyme; and an organic acid or its salt. Methods of use are provided, as well as food products treated with these antibacterial compositions.
Owner:DUPONT NUTRITION BIOSCIENCES APS

Novel food grade lantibiotic from streptococcus macedonicus and uses thereof

InactiveUS20050106662A1Broad inhibitory activity profileEfficient productionBiocideBacteriaBiotechnologyReady to eat
The invention relates to the field of bacteriocin producing microorganisms. The invention more specifically relates to the characterization of a novel food grade bacteriocin, namely a lantibiotic, named macedocin and produced by Streptococcus macedonicus ACA-DC 198. Macedocin inhibit a broad spectrum of lactic acid bacteria as well as several food spoilage and pathogenic bacteria, among others Clostridium tyrobutyricum, and is heat stable and active in a broad pH range. The invention further relates to the use of non-pathogenic microorganisms for producing macedocin in food fermentation processes, such as for preparing milk products, butter, cheese and fermented meat and vegetables, as well as in non-fermented food products such as raw meat, modified atmosphere-packed meat products, ready-to-eat meals, and canned food products, and its use for the preparation of functional starter cultures and cocultures.
Owner:VRIJE UNIV BRUSSEL

Neutralization of bacterial spores

The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., a lantibiotic-based spore decontaminant (e.g., comprising nisin)) and methods of neutralizing (e.g., killing or inhibiting growth or inhibiting germination of) bacteria (e.g., cells and spores). For example, the present invention provides nisin-based compounds (e.g., for bacterial spore decontamination) and methods of using the same in research, therapeutic and drug screening applications.
Owner:BIOSYNEXUS INC

Processes for taste-masking of inhaled formulations

InactiveUS20080138397A1Minimizing bitter tasteMinimizing cough creationBiocideDispersion deliveryPulmonary inhalationThroat irritation
The present invention provides novel processes and methodologies to minimize the bitter or otherwise unpleasant taste, to minimize the tendency to stimulate the cough reflex, or to minimize oropharyngeal deposition of medically-active compounds administered by the pulmonary / inhalation route and to deliver hydroxychloroquine (HCQ) either singularly or in combination with an antimalarial and aminoquinolone by the pulmonary / inhalation route in a sustained release or other formulation that minimizes the bitter or otherwise unpleasant taste of HCQ or any potential to stimulate the cough reflex, and to deliver a dopaminergic compound or its prodrug, including ABT-431 by the pulmonary / inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate the cough reflex, and to deliver a lantibiotic, including duramycin by the pulmonary / inhalation route in a sustained release or other formulation that minimizes the unpleasant taste of the drug or any potential to stimulate throat irritation.
Owner:ARADIGM

Lantibiotics and uses thereof

The present invention provides isolated lantibiotics that inhibit Gram negative and Gram positive microbes. The lantibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have the characteristic of inhibiting growth of a Gram negative microbe in conditions that do not damage the outer membrane of the Gram negative microbe. The present invention also provides methods for making and using the lantibiotics.
Owner:MINNESOTA RGT UNIV OF A CORP OF MN

Composition having bacteristatic and bactericidal activity against bacterial spores and vegetative cells and process for treating foods therewith

Antibacterial compositions effective against both gram positive and gram negative vegetative bacteria plus harmful gram positive sporeforming bacteria include propionibacterial metabolites in combination with two or more of the following: a lantibiotic; a lytic enzyme; and an organic acid or its salt. Methods of use are provided, as well as food products treated with these antibacterial compositions.
Owner:AS DE DANSKE SUKKERFABRIKKER

Antimicrobial composition and method for use

An antimicrobial composition and a method for administering the antimicrobial composition through the water or feed of livestock, wherein the antimicrobial composition is made up of lysozyme and various other agents that act synergistically with lysozyme, such as, dried egg powder, albumen, a sequestering agent and / or a lantibiotic. The composition is used to inhibit the growth of, and diseases and epidemiological significant effects caused by, Clostridium perfinigens, E, coli and Salmonella, in the gut of livestock. More particularly, the antimicrobial composition and method relate to a feed additive that can be administered to poultry and / or swine through their feed. The use of such a feed additive may also inhibit other enteric pathogens that may be present in the gut of livestock.
Owner:NEOVA TECH

Antimicrobial constructs

The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and / or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.
Owner:THE STATE OF OREGON ACTING BY & THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIV +1

Topical anti-infective formulations

Topical compositions containing an effective amount of lysostaphin and / or one or more lantibiotics in a pharmaceutically acceptable carrier for topical application. Methods for treating skin or wound infections, including, but not limited to infected abrasions, skin or surface cuts, burns or surgical incisions or decubiti, with the topical compositions are also disclosed.
Owner:БИОСИНЕКСУС ИНКОРПОРЕЙТЕД

Lantibiotic Carboxyamide Derivatives With Enhanced Antibacterial Activity

The present invention relates to novel amide derivatives of the lantibiotic 97518 and their uses. In particular, the present invention describes novel compounds having general formula (II) and their use as antibiotic.
Owner:SENTINELLA PHARMA INC

Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions

Compositions useful for treating membrane-associated diseases, conditions, and disorders, including inflammatory diseases, dry mouth, primary ciliary dyskinesia and platelet aggregating disorders, are disclosed which comprise at least one lantibiotic compound. Also disclosed are pharmaceutical compositions and methods of treatment for membrane-associated diseases such as inflammation and dermal irritation, as well as use of such compositions in the treatment of membrane-associated diseases, wherein the pharmaceutical compositions contain at least one lantibiotic.
Owner:MOLICHEM MEDICINES INC

Antimicrobial polypeptide, nucleic acid, and methods of use

Antimicrobial compounds and compositions and uses thereof, including the treatment and prevention of bacterial infections are described. The compounds and compositions include lantibiotic polypeptides and the nucleic acid sequences encoding the polypeptides. The compounds and compositions are useful as antimicrobials in antibiotic pharmaceutical preparation and as an antimicrobial or antiseptic dentifrice.
Owner:UNIV OF FLORIDA RES FOUNDATION INC

Method to reduce contamination when culturing mycobacteria

ActiveUS20060078979A1Inhibiting and reducing bacterial contaminationPromote growthBacteriaMicrobiological testing/measurementBacteroidesMycobacterium Infections
Provided is a method for culturing Mycobacteria in the presence of a class A lantibiotic, thereby inhibiting or reducing bacterial contamination in the culture, without significantly disadvantageously affecting or retarding mycobacterial growth. Further provided are the Mycobacteria culture produced thereby, methods for detecting Mycobacteria in a biological sample under conditions that reduce bacterial contamination, and for diagnosing a mycobacterial infection in a biological sample from a subject suspected of having such an infection, as well as, kits useful in practicing such methods.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Formulations for infusion of type b lantibiotics

Described is a A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol such as glycerol and / or a saccharide and optionally a buffer, wherein said final formulation for infusion or direct injection is clear of visual particulates.
Owner:NOVACTA BIOSYSTEMS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products